RAS pathway-driven cancers—such as low-grade serous ovarian cancer and KRAS-mutant non-small cell lung cancer—are difficult to treat. For patients with these forms of cancer, currently available treatments face resistance mechanisms and aren’t effective and often have side effects that make them difficult to tolerate. This means patients quickly run out of therapeutic options. At Verastem Oncology, we’re committed to ensuring options exist. For more information about the work we’re doing at Verastem Oncology, please access our Resources section or contact Julissa Viana via email at media@verastem.com.
Media Resources
Headquartered in Needham, MA, Verastem Oncology Inc. (NASDAQ: VSTM), is a biopharmaceutical company focused on bringing better treatment options to patients who are battling RAS pathway-driven cancers. These types of cancers—which include low-grade serous ovarian cancer and KRAS-mutant non-small cell lung cancer—are extremely difficult to treat and currently available therapeutic options are limited and suboptimal. That’s why new options are needed, and we’re committed to delivering them.
For media interested in Verastem Oncology, please contact Julissa Viana via email at media@verastem.com. You can also refer to the resources below, which contain information about what we do, our leadership team and our financials.
To stay updated on the latest news about Verastem Oncology, sign up for alerts.
Previous and Upcoming Events
Below are past or scheduled upcoming events either hosted or sponsored by Verastem Oncology.
7th Annual Evercore ISI HealthCONx Conference
12/03/2024 11:15 AM (EST)
Guggenheim Healthcare Innovation Conference
11/13/2024 9:00 AM (EST)
Verastem Oncology RAMP 201 Update Call
10/17/2024 4:30 PM (EDT)
2024 Cantor Global Healthcare Conference
09/18/2024 3:40 PM (EDT)
2024 RBCCM Global Healthcare Conference
05/14/2024 3:35 PM (EDT)
B. Riley Securities 4th Annual Oncology Conference
01/18/2024 4:00 PM (EST)
Verastem Inc the Rodman and Renshaw 17th Annual Global Investment Conference
09/10/2015 3:50 PM (EDT)
Verastem Inc at the Jefferies 2015 Healthcare Conference
06/03/2015 10:30 AM (EDT)
Verastem Analyst Breakfast at ASCO
05/31/2015 6:30 AM (CDT)
Verastem Inc at the 2015 UBS Global Healthcare Conference
05/19/2015 1:30 PM (EDT)
Verastem Inc at the Mizuho Securities USA Third Annual Healthcare Corporate Access Day
05/12/2015 12:00 PM (EDT)
Verastem Inc at the Deutsche Bank 40th Annual Healthcare Conference
05/06/2015 3:30 PM (EDT)
Verastem Inc at the 2015 American Association of Cancer Research (AACR) Annual Meeting
04/18/2015 12:00 PM (EDT)
Verastem Inc at the 27th Annual ROTH Conference
03/09/2015 6:30 PM (EDT)
Verastem Inc at the Leerink Global Healthcare Conference
02/11/2015 1:00 PM (EST)
Verastem Inc at the 17th Annual BIO CEO & Investor Conference
02/10/2015 1:30 PM (EST)
Progress Updates and 2015 Outlook
01/08/2015 4:30 PM (EST)
Verastem Inc at Oppenheimer Healthcare Conference
12/10/2014 10:20 AM (EST)
Verastem Inc at the 2014 San Antonio Breast Cancer Symposium (SABCS)
12/09/2014 12:00 PM (EST)
Verastem Inc at the 2014 American Society of Hematology (ASH) Annual Meeting and Exposition
12/06/2014 12:00 PM (EST)
Verastem Inc at the Deutsche Bank BioFest Conference
12/01/2014 3:25 PM (EST)
Verastem Inc at Jefferies Global Heatlhcare Conference - London
11/19/2014 3:40 AM (UTC)
Verastem Inc at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
11/18/2014 12:00 PM (EST)
Live & Breathe: Building a Patient-Centered Biotech
11/10/2014 8:45 AM (EST)
Verastem Inc at 12th International Mesothelioma Interest Group (iMig) Conference
10/22/2014 12:00 PM (EDT)
Articles Featuring Verastem Oncology
Woman, 25, with ovarian cancer recalls symptoms that doctors dismissed: ‘You’re fine’
11/27/2023 Today
Verastem’s new campaign aims to make distinctions in rare type of ovarian cancer
03/17/2023 Endpoints
Mirati and Verastem Combine to Address Unmet Need in KRAS G12C–Mutant NSCLC
01/07/2022 OncLive
Susana Banerjee on Ovarian Cancer Novel Combination Therapy Under Study
11/18/2021 The ASCO Post
11/06/2021 Daily Mail
‘Highly effective’ ovarian cancer treatment could help thousands of women
09/19/2021 The Guardian
Global Study Explores RAF/MEK/FAK Combo in Recurrent LGSOC, With or Without KRAS Mutations
08/06/2021 Targeted Oncology
FDA Designates Avutometinib Plus Defactinib as Breakthrough Therapy for Patients With LGSOC
07/19/2021 Oncology Learning Network
KRAS Pathway Opens Door for Patients With Difficult-to-Treat Ovarian Cancer
06/18/2021 OncLive
Verastem Wins Breakthrough Nod for Combo Therapy in Ovarian Cancer
05/24/2021 Endpoints
05/24/2021 OncLive
FDA Grants Breakthrough Therapy Designation to Combination for Recurrent Ovarian Cancer
05/24/2021 Healio
The RAS Pathway and Cancer: Regulation, Challenges and Therapeutic Progress
05/04/2021 Technology Networks
Personalizing Therapy With Avutometinib, Defactinib for Patients With KRAS+ NSCLC
04/23/2021 Oncology Learning Network
Clinical Trial to Find Optimal Regimen of Avutometinib With or Without Defactinib for LGSOC
04/23/2021 Oncology Learning Network
Dr. Camidge Discusses Launch of Phase 2 Trial Evaluating RAF/MEK Inhibitor in NSCLC
01/13/2021 DocWire News
01/06/2021 OncLive
12/23/2020 Oncology Tube
In the Clinic for December 15, 2020
12/15/2020 BioWorld
12/09/2020 BioPharma Journal
Drs. Banerji and Pachter Talk About RAF/MEK Inhibitor in RAS Mutant Tumors
12/02/2020 DocWire News
Verastem Oncology Launches Phase II Trial of MEK, Pan-RAF Inhibitor in Ovarian Cancer
11/30/2020 Precision Oncology News
11/30/2020 Pharma Premium
11/06/2020 Oncology Tube
KRAS Inhibitors Show Promise in Early Studies
11/05/2020 Cancer Health